Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib and Tamoxifen in Tamoxifen-Resistant Metastatic Breast Cancer
NCT00118157Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2005
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib in breast cancer, sponsored by National Cancer Institute. Primary endpoint: Tumor Response Rate (Complete and Partial) at 4 weeks. Started May 2005; status: completed.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00118157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00118157.